Kyverna Therapeutics (KYTX) Change in Accured Expenses (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Change in Accured Expenses of -$6.9 million for Q1 2026, down 326.93% on a QoQ basis from $3.0 million in Q4 2025, and down 281.15% year-over-year from $3.8 million in Q1 2025.
Kyverna Therapeutics (KYTX) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$6.9 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 281.15% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35000.0 (down 97.96% YoY) and the FY2025 annual result came in at $5.1 million, up 146.6% from the prior year.
- Change in Accured Expenses was -$6.9 million for Q1 2026 at Kyverna Therapeutics, down from $3.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.0 million in Q4 2025 and bottomed at -$6.9 million in Q1 2026.
- A 4-year average of $131000.0 and a median of $719000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2025 — Change in Accured Expenses surged 583.97% — and 2026, when it slumped 281.15%.
- Kyverna Therapeutics' Change in Accured Expenses stood at $957000.0 in 2023, then slumped by 53.71% to $443000.0 in 2024, then jumped by 583.97% to $3.0 million in 2025, then sank by 326.93% to -$6.9 million in 2026.
- Business Quant data shows KYTX's Change in Accured Expenses at -$6.9 million in Q1 2026, $3.0 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Kyverna Therapeutics | 484.08 Mn | 484.08 Mn | - | -6.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.88 Mn |
| Mar 31, 2026 | -6.88 Mn |
| Dec 31, 2025 | 3.03 Mn |
| Dec 31, 2025 | 3.03 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.89 Mn |
| Jun 30, 2025 | 1.89 Mn |
| Mar 31, 2025 | -1.80 Mn |
| Mar 31, 2025 | -1.80 Mn |
| Dec 31, 2024 | 443,000.00 |
| Dec 31, 2024 | 443,000.00 |
| Sep 30, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | 957,000.00 |
| Dec 31, 2023 | 957,000.00 |